AR030188A1 - Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos - Google Patents

Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos

Info

Publication number
AR030188A1
AR030188A1 ARP010100463A ARP010100463A AR030188A1 AR 030188 A1 AR030188 A1 AR 030188A1 AR P010100463 A ARP010100463 A AR P010100463A AR P010100463 A ARP010100463 A AR P010100463A AR 030188 A1 AR030188 A1 AR 030188A1
Authority
AR
Argentina
Prior art keywords
hydrocarbyl
substituted
heterocycle
groups
subject
Prior art date
Application number
ARP010100463A
Other languages
English (en)
Original Assignee
Univ Florida State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida State Res Found filed Critical Univ Florida State Res Found
Publication of AR030188A1 publication Critical patent/AR030188A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos de taxano sustituidos con ésteres en el C7, que tienen la formula: (1) donde Ac es acetilo; Bz es benzoilo; R7 es RaCOO-; R10 es hidroxilo; X3 es alquilo, alquenilo, alquinilo o heterociclo sustituido o insustituido; X5 es ûCOX10, -COOX10 o ûCONHX10; X10 es hidrocarbilo, hidrocarbilo sustituido o heterociclo; y Ra es hidrocarbilo, hidrocarbilo sustituido o heterociclo, donde dicho hidrocarbilo o hidrocarbilo sustituido contiene átomos de carbono en las posiciones alfa y beta respecto del carbono en el cual Ra es un sustituyente. Preferiblemente, los grupos hidrocarbilo o hidrocarbilo sustituido incluyen grupos alquilo, alquenilo, alquinilo y arilo que comprenden de 1 a 20 átomos de carbono. Los sustituyentes pueden incluir halogeno heterociclo, alcoxi, alquenoxi, alquinoxi, ariloxi, hidroxilo, hidroxilo protegido, aciloxi, nitro amino, ciano, tiol, cetales, acetales, y éteres. Preferiblemente, los grupos arilo denotan grupos aromáticos homocíclicos opcionalmente sustituidos, más preferiblemente grupos monocíclicos o bicíclicos que contienen de 6 a 12 átomos de carbono en la porcion del anillo. Preferiblemente el grupo heteroarilo denota grupos aromáticos o no aromáticos monocíclicos o bicíclicos, opcionalmente saturados, completamente saturados o sin saturar, que tienen al menos un heteroátomo en al menos un heteroátomo en el al menos un anillo seleccionado entre átomos de oxígeno, azufre y nitrogeno; y preferiblemente 5 o 6 átomos en cada anillo. Los ejemplos de heterociclos incluyen furilo, tienilo, piridilo, oxazolilo, pirrolilo, indolilo, quinolinilo o isoquinilinilo y semejantes. Los presentes compuestos de taxano tienen excepcional utilidad como agentes antitumor. Composiciones farmacéuticas que comprenden los taxanos y uno o más diluyentes o coadyuvantes inertes o fisiologicamente activos aceptables para el uso farmacéutico. Proceso para tratar un sujeto mamífero que sufre de una condicion que responde a los taxanos que comprende la administracion oral, topica o parenteral al sujeto de la composicion farmacéutica.
ARP010100463A 2000-02-02 2001-01-31 Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos AR030188A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17979400P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
AR030188A1 true AR030188A1 (es) 2003-08-13

Family

ID=22658029

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100463A AR030188A1 (es) 2000-02-02 2001-01-31 Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos

Country Status (35)

Country Link
US (3) US6610860B2 (es)
EP (1) EP1183253B8 (es)
JP (1) JP2003522167A (es)
KR (1) KR100784161B1 (es)
CN (1) CN1362955A (es)
AR (1) AR030188A1 (es)
AT (1) ATE396188T1 (es)
AU (1) AU776051B2 (es)
BG (1) BG65279B1 (es)
BR (1) BR0104749A (es)
CA (1) CA2368993C (es)
CO (1) CO5280224A1 (es)
CZ (1) CZ298484B6 (es)
DE (1) DE60134094D1 (es)
DK (1) DK1183253T3 (es)
ES (1) ES2307588T3 (es)
GE (1) GEP20043322B (es)
HK (1) HK1047938A1 (es)
HU (1) HUP0200917A3 (es)
IL (1) IL145641A0 (es)
MX (1) MXPA01009901A (es)
MY (1) MY137637A (es)
NO (1) NO327982B1 (es)
NZ (1) NZ514409A (es)
PL (1) PL202668B1 (es)
PT (1) PT1183253E (es)
RO (1) RO121777B1 (es)
RU (1) RU2265017C2 (es)
SA (1) SA01220045B1 (es)
SK (1) SK13712001A3 (es)
TR (1) TR200102856T1 (es)
TW (1) TWI291873B (es)
UA (1) UA75573C2 (es)
WO (1) WO2001057027A1 (es)
ZA (1) ZA200108060B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030188A1 (es) 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
CA2367661A1 (en) * 2000-02-02 2001-08-09 Robert A. Holton Taxane formulations having improved solubility
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
KR100819578B1 (ko) * 2001-08-01 2008-04-04 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 C7 에스테르 치환된 탁산
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
US20030082229A1 (en) * 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US8012950B2 (en) * 2003-08-29 2011-09-06 Wisconsin Alumni Research Foundation Method to diagnose and treat degenerative joint disease
EP1810968A3 (en) * 2003-09-25 2007-08-08 Tapestry Pharmaceuticals, Inc. 9, 10-a, a-OH-taxane analogs and methods for production thereof
JP4874102B2 (ja) 2003-09-25 2012-02-15 タペストリー ファーマシューティカルズ インコーポレーテッド 9,10−α,α−OH−タキサンアナログおよびその生成のための方法
CN1960721A (zh) 2004-03-05 2007-05-09 佛罗里达州立大学研究基金有限公司 C7乳酰氧基取代的紫杉烷类
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
JP2008515915A (ja) * 2004-10-07 2008-05-15 エモリー ユニバーシティー 多機能性ナノ粒子結合体およびそれらの使用
DK2336140T3 (en) 2004-10-25 2016-03-21 Dekk Tec Inc Of isophosphoramide mustard salts and analogs thereof as antitumor agents
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
WO2008106621A1 (en) 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008098138A1 (en) 2007-02-07 2008-08-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic macrocyclic compounds for treating cancer
EP2581367B1 (en) 2007-04-06 2015-12-30 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
TWI454266B (zh) 2008-07-31 2014-10-01 Ziopharm Oncology Inc 異磷酸醯胺芥子之鹽類及其類似物的合成及調配物
WO2010099213A1 (en) 2009-02-24 2010-09-02 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
WO2011112867A1 (en) 2010-03-10 2011-09-15 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
JP6127045B2 (ja) 2011-07-11 2017-05-10 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 光増感抗体−蛍光団コンジュゲート
CA2874655C (en) 2012-05-25 2020-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
JP6796058B2 (ja) 2014-08-08 2020-12-02 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ インビトロおよびインビボにおける標的の光制御除去
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
EP3774912A1 (en) 2018-04-10 2021-02-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
AU2020299382A1 (en) 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
US20230057461A1 (en) 2020-01-27 2023-02-23 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
US20240101685A1 (en) 2021-01-29 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
WO2024006965A1 (en) 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
SE463189B (sv) 1989-03-13 1990-10-22 Eston Joensson Preparat avsett att tillfoeras amalgamfyllningar i taender foer att daerigenom hindra eller minska avgaang av kvicksilver eller kvicksilveraanga
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5350866A (en) 1991-09-23 1994-09-27 Bristol-Myers Squibb Company 10-desacetoxytaxol derivatives
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5243045A (en) 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
ES2230790T3 (es) 1992-01-15 2005-05-01 E.R. SQUIBB & SONS, INC. Procedimientos enzimaticos para la resolucion de mezclas enantiomericas de compuestos utiles como intermedios en la preparacion de taxanos.
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
ATE181551T1 (de) 1992-04-17 1999-07-15 Abbott Lab Taxol-derivate
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
HU225294B1 (en) 1992-12-23 2006-09-28 Bristol Myers Squibb Co Oxazoline derivatives for synthesis of sidechain-bearing taxanes and preparation thereof
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
IL109049A (en) * 1993-03-22 2006-12-31 Univ Florida State Texans have a side chain that is converted into pyridyl and pharmaceutical preparations that contain them
DE69425563T2 (de) * 1993-03-22 2001-01-25 Univ Florida State Taxane mit amino-substituierter seitenkette
PT1227093E (pt) * 1993-03-22 2005-09-30 Univ Florida State Beta-cactamas uteis para a preparacao de taxanos possuindo cadeia lateral substituida com furilo ou tienilo
SI0982302T1 (en) 1993-06-11 2004-08-31 Pharmacia & Upjohn Company Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
IL109926A (en) 1993-06-15 2000-02-29 Bristol Myers Squibb Co Methods for the preparation of taxanes and microorganisms and enzymes utilized therein
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
FR2711369B1 (fr) 1993-10-20 1995-11-17 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent.
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5414869A (en) * 1993-11-26 1995-05-16 Thomson; Margaret I. Knotless scarf and method of making same
AU4133096A (en) * 1994-10-28 1996-05-23 Research Foundation Of The State University Of New York, The Taxoid derivatives, their preparation and their use as antitumor agents
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
CA2231837A1 (en) 1995-09-13 1997-03-20 Florida State University Radiosensitizing taxanes and their pharmaceutical preparations
US5767297A (en) 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997042181A1 (en) 1996-05-06 1997-11-13 Florida State University 1-deoxy baccatin iii, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
AU3122597A (en) * 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
EP0914116B1 (en) 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
CA2305399A1 (en) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US5964739A (en) * 1998-06-18 1999-10-12 Champ; Raynido A. Safety disposable needle structure
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
JP2003502401A (ja) 1999-06-21 2003-01-21 ナプロ バイオセラピューティクス,インコーポレイテッド C−2ヒドロキシル保護−n−アシル(2r,3s)−3−フェニルイソセリン活性化エステルおよびそれらの製造方法
WO2001025223A1 (en) * 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
AR030188A1 (es) 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
CA2367661A1 (en) * 2000-02-02 2001-08-09 Robert A. Holton Taxane formulations having improved solubility
WO2001057013A1 (en) 2000-02-02 2001-08-09 Florida State University Research Foundation, Inc. Taxane formulations having improved solubility
IT1319168B1 (it) 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.

Also Published As

Publication number Publication date
CZ298484B6 (cs) 2007-10-17
CN1362955A (zh) 2002-08-07
IL145641A0 (en) 2002-06-30
PL202668B1 (pl) 2009-07-31
HUP0200917A2 (en) 2002-08-28
JP2003522167A (ja) 2003-07-22
HU0200917D0 (en) 2002-04-29
BR0104749A (pt) 2001-12-26
US6610860B2 (en) 2003-08-26
SK13712001A3 (sk) 2002-05-09
BG65279B1 (bg) 2007-11-30
BG105967A (en) 2002-08-30
KR20010111583A (ko) 2001-12-19
ZA200108060B (en) 2003-12-01
HK1047938A1 (zh) 2003-03-14
ES2307588T3 (es) 2008-12-01
MY137637A (en) 2009-02-27
US20040014979A1 (en) 2004-01-22
EP1183253B1 (en) 2008-05-21
EP1183253B8 (en) 2009-01-07
WO2001057027A1 (en) 2001-08-09
KR100784161B1 (ko) 2007-12-12
UA75573C2 (en) 2006-05-15
DK1183253T3 (da) 2008-09-22
AU776051B2 (en) 2004-08-26
NO20014759D0 (no) 2001-10-01
NZ514409A (en) 2004-03-26
TR200102856T1 (tr) 2002-06-21
SA01220045B1 (ar) 2008-06-07
HUP0200917A3 (en) 2004-07-28
CO5280224A1 (es) 2003-05-30
PL350026A1 (en) 2002-10-21
US7186849B2 (en) 2007-03-06
RO121777B1 (ro) 2008-04-30
EP1183253A1 (en) 2002-03-06
TWI291873B (en) 2008-01-01
PT1183253E (pt) 2008-08-04
ATE396188T1 (de) 2008-06-15
GEP20043322B (en) 2003-12-10
CA2368993A1 (en) 2001-08-09
NO20014759L (no) 2001-11-29
NO327982B1 (no) 2009-11-02
US20020013346A1 (en) 2002-01-31
RU2265017C2 (ru) 2005-11-27
CZ20013503A3 (cs) 2002-03-13
MXPA01009901A (es) 2003-07-28
AU3323901A (en) 2001-08-14
DE60134094D1 (de) 2008-07-03
CA2368993C (en) 2009-10-20
US20070249708A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AR030188A1 (es) Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
BRPI0517461A (pt) compostos farmacêuticos
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
GT200000002A (es) Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase.
AR039985A1 (es) Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
PA8462301A1 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR051698A1 (es) Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa
RU94039542A (ru) Производные пиперазина как антагонисты 5-нт-рецепторов, способ получения, фармацевтическая композиция
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PE27499A1 (es) Derivados del 2-(purin-9-il)-tetrahidrofuran-3,4-diol
AR066184A1 (es) Compuesto heterociclico de carboxamida, composicion farmacutica que lo comprende, proceso para prepararla y uso de dicho compuesto solo o en combinacion con un agente antineoplastico para la preparacion de un medicamento util como inhibidor de la akt y dicha combinacion farmaceutica
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
AR035580A1 (es) Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos
KR880009984A (ko) 아데노신 5'-카복사미드 유도체
KR910006241A (ko) 피리미딘-4,6-디카복실산 디아미드, 이의 제조방법, 이의 용도 및 이들 화합물을 기초로 하는 약제
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras

Legal Events

Date Code Title Description
FC Refusal